The Lancet · 2021 · 454 citations · 23 references
MedicineOncologyPharmacologyCancer PharmacologyOncology PharmacotherapyB Cell BiologyB-cell ResponsesCancer ImmunotherapyHematologic Malignancy TherapyLymphoid NeoplasmsRelapsed DiseaseB Cell Survival Pathway InhibitorsB-cell LeukemiaB-cell Malignancy TherapyRelapsed Diffuse Large B-cell Lymphoma
23
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Hematology, Oncology +12
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang, Javier Muñoz, André Goy et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text
Medicine, Hematology, Oncology +15
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text
Medicine, Hematology, Pharmacology +17
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Steven P. Treon, Christina Tripsas, Kirsten Meid et al. · New England Journal of Medicine · 2015 · 931 citations · Full text